The drug and medical-device maker raised its forecast for the year after recording higher sales in the second quarter.

Johnson & Johnson JNJ on Wednesday reported second-quarter 2026 results that topped Wall Street estimates and raised its full ...

The healthcare giant's second-quarter earnings will shine the spotlight on its exciting new products and pipeline.

Johnson & Johnson's Tom Aelbrecht, N-VA's Jan Jambon, Flemish Minister for Welfare and Culture Caroline Gennez, Deputy department head of the nursing department Siska Van den Bergh, ZAS president Els ...

George E. Johnson Sr., the onetime chemist who built Chicago-based Johnson Products, the nation’s largest producer of ...

Johnson & Johnson Q2 2026 results: 6.6% revenue growth, Pharma/MedTech strength, and dividend stability. Click for this JNJ ...

Johnson & Johnson has been dealing for years with thousands of lawsuits related to its talc-based products, which plaintiffs claim gave them cancer. This issue has somewhat affected the drugmaker's ...

On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked her parents to stay home from school, and they gave her one ...

Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding our estimates. The company reported revenue of $22.4 billion and adjusted earnings of ...

Monday - Friday, 6:00 - 7:00 PM ET CNBC's Jim Cramer on Thursday told investors why he thinks the stock of Johnson & Johnson is performing well this year even as the broader healthcare sector lags.